Your browser doesn't support javascript.
loading
Cost-Effectiveness Analysis of Empagliflozin in Comparison to Sitagliptin and Saxagliptin Based on Cardiovascular Outcome Trials in Patients with Type 2 Diabetes and Established Cardiovascular Disease.
Ramos, Mafalda; Foos, Volker; Ustyugova, Anastasia; Hau, Nikco; Gandhi, Pranav; Lamotte, Mark.
Afiliación
  • Ramos M; IQVIA Real World Evidence Solutions, Zaventem, Belgium. mafalda.ramos@be.imshealth.com.
  • Foos V; IQVIA Real World Evidence Solutions, Zaventem, Belgium.
  • Ustyugova A; Boehringer Ingelheim International GmbH, Ingelheim, Germany.
  • Hau N; Boehringer Ingelheim Ltd, Bracknell, UK.
  • Gandhi P; Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, CT, USA.
  • Lamotte M; IQVIA Real World Evidence Solutions, Zaventem, Belgium.
Diabetes Ther ; 10(6): 2153-2167, 2019 Dec.
Article en En | MEDLINE | ID: mdl-31602601
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Tipo de estudio: Etiology_studies / Health_economic_evaluation / Prognostic_studies / Risk_factors_studies Idioma: En Revista: Diabetes Ther Año: 2019 Tipo del documento: Article País de afiliación: Bélgica
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Tipo de estudio: Etiology_studies / Health_economic_evaluation / Prognostic_studies / Risk_factors_studies Idioma: En Revista: Diabetes Ther Año: 2019 Tipo del documento: Article País de afiliación: Bélgica